Crossmark

CD19 CAR T cells for B cell malignancies: a systematic review and meta-analysis focused on clinical impacts of CAR structural domains, manufacturing conditions, cellular product, doses, patient’s age, and tumor types

Crossref DOI link: https://doi.org/10.1186/s12885-024-12651-6

Published Online: 2024-08-22

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Montagna, Erik http://orcid.org/0000-0001-6834-0261
de Campos, Najla Santos Pacheco http://orcid.org/0000-0002-2019-5947
Porto, Victoria Alves http://orcid.org/0000-0003-3640-427X
da Silva, Giselle Correia Próspero http://orcid.org/0000-0002-5679-9734
Suarez, Eloah Rabello http://orcid.org/0000-0002-0521-1056
Funding

Funding for this research was provided by:

Conselho Nacional de Desenvolvimento Científico e Tecnológico (143179/2021-7; 140514/2022-8)

Fundação de Amparo à Pesquisa do Estado de São Paulo (2018/17656-0)
License Information

Text and Data Mining valid from 2024-08-22

Version of Record valid from 2024-08-22
More Information

Article History

Received: 25 May 2023

Accepted: 16 July 2024

First Online: 22 August 2024

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below